Chunling H. Liu
Ueruemqi, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: April 22, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
Journal: The Lancet regional health. Western Pacific
Published: October 30, 2025
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 24, 2025
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025
SH3GL1 mediates B7-H3 recycling and enhances the immune escape in non-small cell lung cancer.
Journal: The International journal of biological markers
Published: August 28, 2025
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 01, 2025
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Journal: BMJ oncology
Published: July 11, 2025
The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer.
Journal: Polish journal of pathology : official journal of the Polish Society of Pathologists
Published: January 24, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 11, 2024
Discover Mutational Differences Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma and Search for More Effective Biomarkers for Immunotherapy.
Journal: Cancer management and research
Published: September 05, 2024
Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
Journal: Journal of cancer research and clinical oncology
Published: August 01, 2024
Last Updated: 09/26/2026